Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2025 Rev YoY: N/A EPS YoY: -12.5% Move: +1.75%

Acasti Pharma Inc

ACST.V

$0.580 1.75%

Exchange TSXV Sector Healthcare Industry Biotechnology

Q3 2025

Published: Feb 13, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for ACST.V

Reported

Report Date

Feb 13, 2025

Quarter Q3 2025

Revenue

N/A

YoY: N/A

EPS

-0.36

YoY: -12.5%

Market Move

+1.75%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

EPS of $-0.36 decreased by 12.5% from previous year
Net income of -4.16M
"N/A" -

ACST.V

Company ACST.V

Period Q3 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 9, 2026

Executive Summary

Acasti Pharma reported a Q3 2025 standing with no quarterly revenue and a material net loss driven primarily by ongoing R&D and general and administrative spend. Revenue remains absent in QQ3 2025, while operating expenses totaled approximately $3.704 million and R&D expense reached $2.194 million, contributing to an EBITDA of about -$3.702 million and a net income of -$4.156 million (-$0.36 per share). The company displays strong liquidity metrics, with a current ratio of 6.06 and a cash ratio of 5.61, underscoring balance sheet resilience despite the cash burn typical of a pre-revenue biotech. Management’s strategic focus continues to center on CaPre (the cardiovascular program) and pursuing strategic partnerships that could unlock near-term value through upfronts, milestones, or collaboration economics. Absent revenue, the near-term equity story hinges on successful partnerships or other value-enhancing strategic moves rather than operating leverage or margin expansion.

Key Performance Indicators

Operating Income

Increasing

-3.70M

QoQ: 23.33% | YoY: 8.13%

Net Income

Decreasing

-4.16M

QoQ: -21.07% | YoY: -73.78%

EPS

Decreasing

-0.36

QoQ: -20.00% | YoY: -12.50%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: None reported in QQ3 2025 (N/A YoY/QoQ data provided).
Gross Profit: -$2,000; Gross Profit Margin data not provided. Note: With no product revenue, gross profit is effectively a near-term negative driven by cost of revenue allocations.
Operating Income: -$3,704,000 for QQ3 2025; YoY QoQ comparisons not directly available due to absence of reported revenue in prior periods.
EBITDA: -$3,702,000; EBITDA margin not reported.
Net Income: -$4,155,000; YoY change is -73.78% and QoQ change is -21.07% per earnings data.
EPS (Diluted): -$0.36; YoY EPS change -12.50%; QoQ change -20.00%.
Key balance sheet and liquidity indicators: Current Ratio 6.06; Quick Ratio 6.06; Cash Ratio 5.61; Debt Ratio 0; Company Equity Multiplier ~1.174; Cash per Share ~$0.961. Weighted average shares outstanding: 11.506 million.
Efficiency/Turnover: Receivables Turnover 0; Payables Turnover 0.00301; Inventory Turnover 0; Asset Turnover 0. Overall, operating leverage is not meaningful in a pre-revenue environment.

Income Statement

Metric	Value	YoY Change	QoQ Change
Gross Profit	-2.00K	99.93%	0.00%
Operating Income	-3.70M	8.13%	23.33%
Net Income	-4.16M	-73.78%	-21.07%
EPS	-0.36	-12.50%	-20.00%

Key Financial Ratios

Return on Assets

Weak

-0.07%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.08%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

6.06

Current ratio indicates excellent liquidity and financial flexibility

P/E Ratio

Negative

-2.59x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.83x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2026	0.00	-0.06	+0.0%	View
Q1 2026	0.00	-0.21	+0.0%	View
Q4 2025	0.01	0.05	+0.0%	View
Q3 2025	0.00	-0.36	+0.0%	View
Q2 2025	0.00	-0.30	+0.0%	View

ACST.V

Acasti Pharma Inc

Q2 2026 Report

Acasti Pharma Inc (ACST.V) QQ2 2026 Results – Narrow Loss, Strong Liquidity, and CaPre Partnerships Focus...

Read full report

ACST.V

Acasti Pharma Inc

Q1 2026 Report

Acasti Pharma Inc (ACST.V) QQ1 2026 Results: Liquidity Backdrop Intact Amid Revenue Pause and Persistent Losses...

Read full report

ACST.V

Acasti Pharma Inc

Q4 2025 Report

Acasti Pharma Inc (ACST.V) QQ4 2025 Results — Modest Revenue, Strong Liquidity and Net Income Uplift Driven by Non-Operating Items as R&D Push Conti...

Read full report

ACST.V

Acasti Pharma Inc

Q2 2025 Report

Acasti Pharma Inc (ACST.V) QQ2 2025 Results – Narrow Top-Line Activity, Ongoing R&D Burn, and Liquidity Support in a Tight Biotech Environment...

Read full report

Acasti Pharma Inc (ACST.V) Q3 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More ACST.V Quarterly Reports

ACST.V

ACST.V

ACST.V

ACST.V

Related Financial Data

Sector Analysis: Healthcare

ACST.V Full Profile

ACST.V Financial Statements

Earnings Calendar